EU Approves Self-Administration Routes for Rozanolixizumab for Myasthenia Gravis

UCB’s rozanolixizumab introduces two new self-administration methods, empowering patients with generalized myasthenia gravis (gMG) to manage their treatment with greater independence and control.:

Source: Neurology Read More